Loading institutional data...
Loading institutional data...
Held by 246 of 5,944 reporting institutions (93th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $727.3M 100.0% | $660.6M 100.0% | $591.6M 100.0% | $509.7M 100.0% | $484.3M 100.0% | $444.4M 100.0% | $408.8M 100.0% | $276.7M 100.0% | $240.3M 100.0% | $231.8M 100.0% |
| Cost of Revenue | $413.0M 56.8% | $370.5M 56.1% | $347.0M 58.7% | $321.8M 63.1% | $297.3M 61.4% | $258.6M 58.2% | $212.0M 51.9% | $149.5M 54.0% | $138.3M 57.6% | $133.7M 57.7% |
| Cost of Services | — | — | — | — | — | — | — | — | $138.3M 57.6% | $133.7M 57.7% |
| Gross Profit | $314.3M 43.2% | $290.1M 43.9% | $244.6M 41.3% | $187.9M 36.9% | $187.1M 38.6% | $185.9M 41.8% | $196.8M 48.1% | $127.3M 46.0% | $102.0M 42.4% | $98.1M 42.3% |
| Research & Development | $37.1M 5.1% | $31.2M 4.7% | $27.3M 4.6% | $30.3M 5.9% | $21.9M 4.5% | $8.2M 1.9% | $8.5M 2.1% | $3.0M 1.1% | $3.6M 1.5% | $4.6M 2.0% |
| Selling, General & Admin | $273.3M 37.6% | $259.7M 39.3% | $243.1M 41.1% | $243.4M 47.7% | $221.3M 45.7% | $143.8M 32.4% | $128.0M 31.3% | $84.8M 30.7% | $70.4M 29.3% | $63.9M 27.6% |
| Total Operating Expenses | $430.2M 59.1% | $382.2M 57.9% | $352.3M 59.6% | $345.5M 67.8% | $305.8M 63.1% | $199.9M 45.0% | $183.8M 45.0% | $117.2M 42.4% | $99.1M 41.2% | $95.9M 41.4% |
| Operating Income | -$115.9M -15.9% | -$92.1M -13.9% | -$107.7M -18.2% | -$157.6M -30.9% | -$118.8M -24.5% | -$14.0M -3.1% | $13.0M 3.2% | $10.0M 3.6% | $2.9M 1.2% | $2.2M 0.9% |
| Interest Expense | $3.8M 0.5% | $6.6M 1.0% | $6.9M 1.2% | $7.6M 1.5% | $8.2M 1.7% | $7.0M 1.6% | $3.7M 0.9% | $6.2M 2.3% | $5.5M 2.3% | $10.0M 4.3% |
| Interest & Investment Income | $9.1M 1.2% | $18.4M 2.8% | $16.9M 2.9% | $6.1M 1.2% | — | — | — | — | — | — |
| Other Income (Expense), net | $296K 0.0% | -$379K -0.1% | $644K 0.1% | -$213K -0.0% | -$499K -0.1% | $7.9M 1.8% | -$4.6M -1.1% | $14K 0.0% | -$12K -0.0% | $0 0.0% |
| Pretax Income | -$110.3M -15.2% | -$80.7M -12.2% | -$97.1M -16.4% | -$159.3M -31.3% | -$15.1M -3.1% | -$14.1M -3.2% | $3.6M 0.9% | $3.8M 1.4% | -$2.6M -1.1% | -$7.8M -3.4% |
| Income Tax Expense | -$2.2M -0.3% | -$1.9M -0.3% | -$9.1M -1.5% | -$15.1M -3.0% | -$6.7M -1.4% | -$18.2M -4.1% | -$4.4M -1.1% | $1.2M 0.4% | -$2.3M -0.9% | -$1.7M -0.7% |
| Net Income | -$108.0M -14.8% | -$79.0M -12.0% | -$88.0M -14.9% | -$144.0M -28.3% | -$8.0M -1.7% | $4.2M 0.9% | $8.0M 2.0% | $2.6M 1.0% | -$396K -0.2% | -$6.1M -2.6% |
| Per Share | ||||||||||
| Weighted Avg Shares (Basic) | 128.1M | 126.7M | 125.5M | 124.2M | 120.0M | 108.6M | 100.5M | 85.6M | 79.4M | 77.5M |
| Weighted Avg Shares (Diluted) | 128.1M | 126.7M | 125.5M | 124.2M | 120.0M | 111.8M | 103.6M | 91.6M | 79.4M | 77.5M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor; leverage rising year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$22M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -9%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $160M covers all $99M of scheduled principal — no refinancing pressure. Scheduled principal only (excludes interest & revolver draws). As of 2017-03-31 (10-Q).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~1.1% on $342M of debt.
Cash of $160M fully covers short-term debt of $0.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-09-17
Where each multiple sits in its own 14-yr range · 40th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 2.6× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 54.0 | 51.9 | 58.2 | 61.4 | 63.1 | 58.7 | 56.1 | 56.8 |
| Gross Profit | 46.0 | 48.1 | 41.8 | 38.6 | 36.9 | 41.3 | 43.9 | 43.2 |
| R&D | 1.1 | 2.1 | 1.9 | 4.5 | 5.9 | 4.6 | 4.7 | 5.1 |
| SG&A | 30.7 | 31.3 | 32.4 | 45.7 | 47.7 | 41.1 | 39.3 | 37.6 |
| Operating Income | 3.6 | 3.2 | -3.1 | -24.5 | -30.9 | -18.2 | -13.9 | -15.9 |
| Income Tax | 0.4 | -1.1 | -4.1 | -1.4 | -3.0 | -1.5 | -0.3 | -0.3 |
| Net Income | 1.0 | 2.0 | 0.9 | -1.7 | -28.3 | -14.9 | -12.0 | -14.8 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on NEO: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| NEO | $2.6B | — | — | 3.5× | 10.1% | 43.2% | -14.9% | -12.9% | -9.2% | -4.3× | 246 |
Peers = companies sharing NEO's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.